Atara Bio Announces Third Quarter 2016 Financial Results and Recent Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
ATARA Biotherapeutics (ATRA) Misses Q3 EPS by 9c
November 4, 2016 8:18 AM EDTATARA Biotherapeutics (NASDAQ: ATRA) reported Q3 EPS of ($0.88), $0.09 worse than the analyst estimate of ($0.79).
For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.
... More